Reexploring 5-methoxyindole-2-carboxylic acid (MICA) as a potential antidiabetic agent

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

5-Methoxyindole-2-carboxylic acid (MICA) is a potent hypoglycemic agent that inhibits gluconeogenesis in the liver. It is also a well-known inhibitor of mitochondrial dihydrolipoamide dehydrogenase. MICA was extensively studied in the 1960s and 1970s and was once tested for its antidiabetic effect in diabetic Chinese hamsters, whereby MICA was shown to exhibit pronounced glucose-lowering ability while also leading to increased rate of death of the diabetic animals. Since then, MICA’s potential ability in lowering blood glucose in diabetes has never been revisited. In my opinion, MICA should be comprehensively reexplored for its antidiabetic properties in a variety of rodent diabetes models. For a given animal model, its dose-dependent effect and the effects of different routes of administrations as well as its synergistic effects with other glucose-lowering drugs should also be investigated. More studies in the future on this chemical may provide novel insights into its role as an antidiabetic agent.

Original languageEnglish
Pages (from-to)183-186
Number of pages4
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Volume11
DOIs
StatePublished - 1 Jan 2018

Fingerprint

Hypoglycemic Agents
Dihydrolipoamide Dehydrogenase
Glucose
Gluconeogenesis
Cricetulus
Blood Glucose
Rodentia
Animal Models
Mortality
5-methoxyindole-2-carboxylic acid
Liver
Pharmaceutical Preparations

Keywords

  • 5-methoxyindole-2-carboxylic acid
  • Antidiabetic
  • Diabetes
  • Dihydrolipoamide dehydrogenase
  • Gluconeogenesis
  • Mitochondria

Cite this

@article{c293bc652080475d87593c3780be96e9,
title = "Reexploring 5-methoxyindole-2-carboxylic acid (MICA) as a potential antidiabetic agent",
abstract = "5-Methoxyindole-2-carboxylic acid (MICA) is a potent hypoglycemic agent that inhibits gluconeogenesis in the liver. It is also a well-known inhibitor of mitochondrial dihydrolipoamide dehydrogenase. MICA was extensively studied in the 1960s and 1970s and was once tested for its antidiabetic effect in diabetic Chinese hamsters, whereby MICA was shown to exhibit pronounced glucose-lowering ability while also leading to increased rate of death of the diabetic animals. Since then, MICA’s potential ability in lowering blood glucose in diabetes has never been revisited. In my opinion, MICA should be comprehensively reexplored for its antidiabetic properties in a variety of rodent diabetes models. For a given animal model, its dose-dependent effect and the effects of different routes of administrations as well as its synergistic effects with other glucose-lowering drugs should also be investigated. More studies in the future on this chemical may provide novel insights into its role as an antidiabetic agent.",
keywords = "5-methoxyindole-2-carboxylic acid, Antidiabetic, Diabetes, Dihydrolipoamide dehydrogenase, Gluconeogenesis, Mitochondria",
author = "Liang-Jun Yan",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/DMSO.S166485",
language = "English",
volume = "11",
pages = "183--186",
journal = "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy",
issn = "1178-7007",
publisher = "Dove Medical Press Ltd.",

}

Reexploring 5-methoxyindole-2-carboxylic acid (MICA) as a potential antidiabetic agent. / Yan, Liang-Jun.

In: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 11, 01.01.2018, p. 183-186.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Reexploring 5-methoxyindole-2-carboxylic acid (MICA) as a potential antidiabetic agent

AU - Yan, Liang-Jun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - 5-Methoxyindole-2-carboxylic acid (MICA) is a potent hypoglycemic agent that inhibits gluconeogenesis in the liver. It is also a well-known inhibitor of mitochondrial dihydrolipoamide dehydrogenase. MICA was extensively studied in the 1960s and 1970s and was once tested for its antidiabetic effect in diabetic Chinese hamsters, whereby MICA was shown to exhibit pronounced glucose-lowering ability while also leading to increased rate of death of the diabetic animals. Since then, MICA’s potential ability in lowering blood glucose in diabetes has never been revisited. In my opinion, MICA should be comprehensively reexplored for its antidiabetic properties in a variety of rodent diabetes models. For a given animal model, its dose-dependent effect and the effects of different routes of administrations as well as its synergistic effects with other glucose-lowering drugs should also be investigated. More studies in the future on this chemical may provide novel insights into its role as an antidiabetic agent.

AB - 5-Methoxyindole-2-carboxylic acid (MICA) is a potent hypoglycemic agent that inhibits gluconeogenesis in the liver. It is also a well-known inhibitor of mitochondrial dihydrolipoamide dehydrogenase. MICA was extensively studied in the 1960s and 1970s and was once tested for its antidiabetic effect in diabetic Chinese hamsters, whereby MICA was shown to exhibit pronounced glucose-lowering ability while also leading to increased rate of death of the diabetic animals. Since then, MICA’s potential ability in lowering blood glucose in diabetes has never been revisited. In my opinion, MICA should be comprehensively reexplored for its antidiabetic properties in a variety of rodent diabetes models. For a given animal model, its dose-dependent effect and the effects of different routes of administrations as well as its synergistic effects with other glucose-lowering drugs should also be investigated. More studies in the future on this chemical may provide novel insights into its role as an antidiabetic agent.

KW - 5-methoxyindole-2-carboxylic acid

KW - Antidiabetic

KW - Diabetes

KW - Dihydrolipoamide dehydrogenase

KW - Gluconeogenesis

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=85059046588&partnerID=8YFLogxK

U2 - 10.2147/DMSO.S166485

DO - 10.2147/DMSO.S166485

M3 - Article

VL - 11

SP - 183

EP - 186

JO - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

JF - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

SN - 1178-7007

ER -